Haematopoietic stem cell transplantation in Hong Kong by Liang, R et al.
Title Haematopoietic stem cell transplantation in Hong Kong
Author(s) Lie, AKW; Au, WY; Liang, R
Citation
The 2009 Chinese Blood & Marrow Transplantation Forum, Hong
Kong, 27-28 February 2009. In Hong Kong Medical Journal, 2009,
v. 15, suppl. 3, p. 17-21
Issued Date 2009
URL http://hdl.handle.net/10722/62297
Rights Creative Commons: Attribution 3.0 Hong Kong License
	 Hong	Kong	Med	J		Vol	15	No	3	Supplement	3	June	2009	 17
Introduction
In Hong Kong, the first case of haematopoietic stem cell transplant (HSCT) was performed 
at the Bone Marrow Transplant Center, Queen Mary Hospital (QMH) in May 1990 for a 
female patient with acute myeloblastic leukaemia (AML) with human leukocyte antigen 
(HLA)–matched sibling donor.1 Since then three more transplant centres have been 
established, including Prince of Wales Hospital (PWH) in 1991, Queen Elizabeth Hospital 
in 1995, and Tuen Mun Hospital in 2006. Paediatric HSCT, both autologous and allogeneic, 
is performed at QMH and PWH. For adult patients, autologous HSCT is performed at all 
four hospitals while QMH is the only centre for allogeneic HSCT in adults. Unfortunately, 
a central registry of all HSCT activities is yet to be established in Hong Kong. Such a 
central registry is desirable not only for monitoring HSCT activities, but also for gathering 
information on long-term survival, late complications, uncommon conditions as well as 
changes in trends over the years which will help in planning the HSCT service for the 
future. Unofficial estimates of about 170 HSCTs are performed annually and a total of a 
little over 2000 HSCTs have been performed up to the end of 2008. Among the latter, 1708 
(approximately 85%) were performed at QMH at a rate of about 130 per annum.
Haematopoietic stem cell transplant at Queen Mary Hospital
Among the 1708 HSCTs performed in QMH, 1417 (83%) were first-time transplants and 
the rest (291, 17%) were repeat transplants most commonly for disease relapse, less often 
for graft failure or secondary haematological malignancy (Fig 1). There was a slight male 
predominance among the patients (male 56%, female 44%). The median age at transplant 
was 35.4 years (range, 3 months to 67 years) [Fig 2] with 14.2% of the transplants performed 
in children and adolescent (ie <18 years), and the remaining 85.8% in adults.
 Starting with bone marrow transplant (BMT) only in 1990, the first case of peripheral 
blood stem cell transplant (PBSCT) was performed for a female patient with relapsed non-
Hodgkin’s lymphoma (NHL) in 1992. Over the years, the annual number of PBSCT has 
overtaken BMT. In recent years, while the use of PBSCT is roughly equal to that of BMT 
in allogeneic transplant, it is almost 4 times that of BMT in autologous transplant. Bone 
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The first case of haematopoietic stem cell transplant (HSCT) was performed at the Bone 
Marrow Transplant Center, Queen Mary Hospital (QMH) in 1990. Since then three more 
transplant centres have been established: Prince of Wales Hospital (1991) mainly in paediatric 
transplant, Queen Elizabeth Hospital (1995) and Tuen Mun Hospital (2006) in adult autologous 
transplant. Up to the end of 2008, a little over 2000 transplants have been performed in 
Hong Kong, and QMH takes up about 85% of the total number of cases. A unified HSCT 
registry in Hong Kong is desirable and is yet to be established. At QMH, by the end of 2008, 
a total of 1708 transplant procedures have been performed with 83% (1417) being first-time 
transplants and the rest (291, 17%) are repeat transplants mostly for relapsed patients. The 
numbers of male and female patients are 955 and 753, respectively. The median age is 35.4 
years (range, 3 months to 67 years) with 85.8% of the transplants performed in adults (>18 
years). The type of donor includes 34% autologous, 1% syngeneic, 38% related allogeneic 
and 27% unrelated allogeneic. The top five indications of the first-time transplants are acute 
myeloid leukaemia (25.8%), chronic myeloid leukaemia (15.9%), lymphoma (14.6%), acute 
lymphoblastic leukaemia (14.5%), and myeloma (8.6%). With the development of peripheral 
blood stem cell collection, in recent years it is performed in 50% of the allogeneic and 80% of 
the autologous cases. Bone marrow harvest in autologous cases is only for patients who fail 
peripheral blood stem cell mobilisation. Transplant outcomes are reported to the Center for 
International Blood and Marrow Transplant Research and long-term survivals are in general 
comparable to international standard.
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香港首宗血液幹細胞移植，於1990年在瑪麗醫院的骨髓移植中心進
行。此後，威爾斯親王醫院於1991年開展兒童骨髓移植，而伊利沙伯
醫院及屯門醫院亦於1995及2006年開展成人自體移植。截至2008年
底，全港共已進行稍多於二千宗移植治療，而瑪麗醫院佔其中大約
85%。目前香港仍有待發展出一個全港的血液幹細胞移植檔案庫。截
至2008年底，瑪麗醫院已進行1708宗移植。其中83%（1417）為病
者首次移植，其餘17%（291）主要因復發而重做。男女人數為955和
753。中位年齡為35.4歲（由3個月至67歲），其中85.8%為18歲以
上成人。供者分別為：34%自體、1%同基因、38%親屬異體及27%非
親屬。首五項病症為：25.8%急粒、15.9%慢粒、14.6%淋巴瘤、
14.5%急淋及8.6%骨髓瘤。隨著外周血幹細胞之普及，近年本中心有
50%之異體及80%之自體移植皆應用此法。四份一之自體移植仍因採
集外周血遇困難而用骨髓。本中心之所有移植後之跟進資料皆提供及
CIBMTR，而長遠的存活數據大至興國際水平相約。
香港血液幹細胞移植概況
marrow harvest is basically reserved for patients 
in whom PBSC harvest has failed or is expected to 
have poor yield due to extensive prior chemotherapy 
and/or radiotherapy. Hence, to ensure patients can 
benefit from the earlier engraftment with autologous 
PBSCT, timely consideration and early referral is of 
key importance.
 Cord blood transplant (CBT) was first performed 
in 1994 for a 3-year-old girl with beta thalassaemia 
major using stem cells from an HLA-matched sibling, 
and unrelated CBT was first performed in 1998 for a 
9-year-old boy with acute lymphoblastic leukaemia 
(ALL). Up to the end of 2008, a total of 31 CBTs have 
been performed mainly in paediatric and adolescent 
patients, and only four CBTs in adults.
 The types of donor among the 1708 HSCTs 
include autologous (34%), syngeneic (1%), siblings 
(35%), other related donors (3%) and unrelated donors 
(27%). There is a trend with increasing proportion of 
autologous and unrelated HSCTs compared to related 
donations (Fig 3).
 Among the paediatric patients, besides 
haematological malignancies, beta thalassaemia 
major,2 congenital immunodeficiency syndromes3 
(eg severe combine immunodeficiency syndrome 
and Wiskott-Aldrich syndrome), paediatric solid 
tumours (eg neuroblastoma, rhabdomyosarcoma 
and medulloblastoma) and other congenital diseases 
(eg Diamond-Blackfan anaemia, Fanconi anaemia, 
dyskeratosis congenital and infantile osteopetrosis) 
make up a small but important fraction of curable 
patients (Table 1). For adults, the top five indications 
of the first-time transplants are AML (25.8%), chronic 
myeloid leukaemia (CML) (15.9%), NHL (14.6%), 
ALL (14.5%) and multiple myeloma (MM) (8.6%). In 
subsequent discussion, we shall focus on these five 
conditions, which make up approximately three 
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FIG 1.  Number of attempts with haematopoietic stem cell 
transplant (HSCT) received by patients at Queen Mary Hospital
Total HSCT: 1708; 1st HSCT: 1417; 2nd or more HSCT: 291
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FIG 2.  Patients’ age at haematopoietic stem cell transplantation
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quarters of all HSCTs at QMH. The numbers of HSCTs 
for all five conditions are on an increasing trend 
over the years, except CML where there is a marked 
decrease since 2005 when imatinib became available 
for all such patients under the safety net scheme 
of the Hospital Authority. The increase in HSCT is 
particularly marked with MM in recent years, largely 
as a result of improved disease control with newer 
agents, such as bortezomib and thalidomide.4,5
Acute myeloid leukaemia
Of 231 patients—116 were in first complete remission 
(CR1), 58 in second complete remission (CR2), and 57 
not in remission (NR)—having HLA-matched sibling 
HSCT, the respective overall survival (OS) at 5 and 
10 years were 56.9% and 55.6% with CR1, 48.6% and 
45.9% with CR2, and 18.2% and 15.6% with NR (Table 
3).
 For 59 HLA-matched unrelated HSCT (28 in CR1, 
21 in CR2, and 10 in NR), the 5-year OS were 68.0% 
with CR1, 37.8% with CR2, and 25.9% with NR. The 
usual conditioning regimen is busulphan (Bu) 16 mg/
m2 over 4 days plus cyclophosphamide (Cy) 120 mg/
kg over 2 days in HLA-matched sibling HSCT,6 while 
for unrelated HSCT the Cy is increased to 150 mg/kg 
over 3 days.
Chronic myeloid leukaemia
Chronic myeloid leukaemia used to make up about a 
quarter of all the HSCTs annually and the conditioning 
regimen is Bu-Cy as in AML. With the introduction 
of imatinib, it has dropped to less than 5% in recent 
years. With 185 HLA-matched sibling HSCT, the 
10-year disease-free survival (DFS) with chronic 
phase (CP, n=140), accelerated phase (AP, n=37) and 
blastic crisis (BC, n=8) were 53.0%, 25.0% and 0.0%, 
respectively. However, having effective salvage 
therapy in relapsed cases, such as termination of 
immunosuppression or donor leukocyte infusion in 
the past, and more recently with imatinib treatment, 
10-year OS can still be maintained at 76.6% for CP and 
25.7% for AP patients.
 Only a small number of CML patients received 
unrelated HSCT (24 CP, 17 AP, and 6 BC; total=47), the 
10-year OS are much the same for the different stages 
(52.6% for CP, 50.0% for AP, and 41.7% for BC).
Non-Hodgkin’s lymphoma
A total of 148 patients received autologous HSCT 
with 24 in CR1, 65 in partial remission, 39 in CR2, and 
20 in NR. The 10-year OS for the first three groups 
were 82.1%, 60.4% and 53.4%, respectively, while NR 
patients had very poor OS.
 Allogeneic HSCT was performed for 73 patients 
of whom 63 were related donors (61 siblings, 2 others) 
and 10 were unrelated. Sixty-one patients had stage-IV 
disease at presentation and received direct allogeneic 
HSCT after initial disease control. The remaining 
12 patients relapsed after initial autologous HSCT 
and then received second-time allogeneic HSCT as 
salvage. The histological diagnoses are as listed in 
Table 2. The conditioning regimen were Cy (120 mg/kg 
over 2 days) and total body irradiation (TBI; 12 Gy in 6 
fractions over 3 days) in 47 patients, CBV7 (carmustine 
100 mg/m2 daily day 1 to 3, etoposide 400 mg/m2 every 
12 hours from day 1 to 3, Cy 1800 mg/m2 daily day 4 to 
7) in 19, and other myeloablative regimens in 7. The 
5-year OS was 57.5% in the direct allogeneic HSCT 
group and 45.7% with the second-time allogeneic 
HSCT group, showing no statistically significant 
difference between the two groups (P=0.447).
Indication %
Acute myeloblastic leukaemia 25.8
Chronic myeloid leukaemia 15.9
Non-Hodgkin’s lymphoma 14.6
Acute lymphoblastic leukaemia 14.5
Multiple myeloma 8.6
Myelodysplastic syndrome 5.8
Paediatric solid tumours 2.6
Beta thalassaemia major 2.5
Severe aplastic anaemia 2.3
Adult solid tumours 1.8
Hodgkin’s lymphoma 1.7
Immunodeficiency syndrome 1.6
Other congenital diseases 1.4
Acute biphenotypic leukaemia 1.1
TABLE 1. Indications for haematopoietic stem cell transplant
Histological diagnosis No. of patients (n=73)
Diffuse large B cell 28
Lymphoblastic 12
Mantle cell 8
T/NK nasal-type cell 6
Peripheral T cell (NOS) 5
Burkitt’s lymphoma 5
Follicular 4
Anaplastic large T cell 2
Angioimmunoblastic T cell 1
Maltoma 1
Marginal zone B cell 1
TABLE 2. WHO classification of non-Hodgkin’s lymphoma with 
allogeneic haematopoietic stem cell transplant
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Disease Type of HSCT† Stage No. of patients 5-Year 10-Year
DFS (%) OS (%) DFS (%) OS (%)
AML Sib CR1 116 50.3 56.9 47.3 55.6
CR2 58 43.2 48.9 40.5 45.9
NR 57 12.3 18.2 12.3 15.6
AML Unrelated CR1 28 52.5 68.0 - -
CR2 21 37.8 37.8 - -
NR 10 25.9 25.9 - -
ALL Sib CR1 77 44.0 47.0 43.8 43.8
CR2 27 18.3 26.2 18.3 21.0
NR 9 0 16.7 - -
ALL Unrelated CR1 27 57.1 57.9 - -
CR2 7 35.7 42.9 35.7 42.9
NR 1 0 0 0 0
CML Sib CP 140 61.4 81.3 53.0 76.6
AP 37 37.7 38.5 25.0 25.7
BC 8 12.5 12.5 0 0
CML Unrelated CP 24 39.7 52.6 39.7 52.6
AP 17 47.1 50.0 47.1 50.0
BC 6 33.3 47.1 0 0
NHL Autologous CR1 24 - 82.1 - 82.1
PR 65 - 63.6 - 60.4
CR2 39 - 57.0 - 53.4
NR 20 - - - -
NHL Direct allo 61 50.1 57.5 50.1 57.5
Prior auto 12 25.0 45.7 - -
MM Autologous 88 - 36.0 - 28.8
Allo MT 14 - 61.4 - 30.7
Allo NMT 33 - 33.8 - -
TABLE 3. Survival data of the top five adult conditions transplanted at Queen Mary Hospital*
* AML denotes acute myeloid leukaemia, ALL acute lymphoblastic leukaemia, CML chronic myeloid leukaemia, NHL non-Hodgkin’s lymphoma, MM multiple 
myeloma, CR1 first complete remission, CR2 second complete remission, NR not in remission, CP chronic phase, AP accelerated phase, BC blastic crisis, PR partial 
remission, DFS disease-free survival, and OS overall survival
† Sib: HLA-matched sibling HSCT; Unrelated: HLA-matched unrelated HSCT; Direct alo: directed allogeneic HSCT; Prior auto: prior autologous HSCT; Allo MT: 
allogeneic myeloablative HSCT; Allo NMT: allogeneic non-myeloablative HSCT
Acute lymphoblastic leukaemia
In 2007, we published our long-term results of 
allogeneic HSCT for 108 adult ALL patients.8 Eighty-
seven (80.6%) patients had HLA-matched sibling 
HSCT while the rest (21, 19.4%) had unrelated HSCT. 
Most of the patients (n=100, 92.6%) had Cy-TBI 
as conditioning and the remaining had CBV. Not 
surprisingly, higher incidence of acute graft-versus-
host disease (aGVHD) was noted with unrelated 
HSCT. The incidence of grade 0, 1/2 and 3/4 aGVHD 
with sibling HSCT were 59.8%, 22.9% and 17.2%, 
respectively; and with unrelated HSCT were 33.3%, 
52.4% and 14.3%, respectively. It is interesting to 
note that the DFS and OS were higher in patients 
with grade 1/2 aGVHD compared with grade 0 or 3/4. 
While the transplant-related mortality was the same 
between sibling and unrelated HSCT, the unrelated 
HSCT was associated with lower relapse rate and 
higher DFS compared with the sibling group. Our 
data also indicate better DFS and OS rates with earlier 
stage of disease (CR1>CR2>NR).
Plasma cell myeloma
A total of 135 patients with MM received autologous, 
myeloablative allogenic and non-myeloablative 
allogeneic HSCT (88, 14, and 33, respectively) showing 
no significant difference in OS. Nevertheless, with 
the small number of myeloablative allogeneic HSCTs, 
patients younger than 40 years (n=9) has significantly 
better OS than those over 40 years (n=5) [P<0.015]. This 
perhaps leaves the controversy of whether allogenic 
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HSCT is indicated for MM open for discussion.
 Recently, we have just completed a study in 
24 patients using conventional VAD (vincristine, 
adriamycin, dexamethasone) thrice as induction 
treatment. After VAD treatment, patients with 
paraprotein response over 75% were to receive 
autologous PBSCT with melphalan 200 mg/m2 
conditioning. Patients with less than 75% response 
were then salvaged with combination chemotherapy 
of bortezomib, thalidomide and dexamethasone 
(VTD) four times before autologous PBSCT. 
Preliminary results indicate improved response 
could be achieved with VTD salvage, and autologous 
PBSCT further enhanced CR rate. Encouraged by such 
results and those of Oakervee et al,9 we have started 
on a new PAD study incorporating bortezomib into 
first-line therapy followed by autologous HSCT.
Conclusion
Over the years, we have certainly seen a changing 
trend in HSCT in Hong Kong with increasing use of 
PBSCT especially in autologous HSCT, increasing use of 
unrelated donor and cord blood, marked reduction in 
HSCT for CML but increasing numbers for MM. It is of 
utmost importance that the role of HSCT should always 
be considered in the light of other advances in treatment 
of haematological diseases, so that patients may benefit 
most from a well-planned treatment strategy and suffer 
the least of morbidity and mortality.
